Finance

Beta
Lists
NEOG:NASDAQ
Neogen Corp
USD 8,93
-4,08%
(-0,38) 1D
USD 8,82
-1,23% (-0,11)
After hours
Closed: 17 Jun., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NEOG...
Open
USD 9,26
High
USD 9,43
Low
USD 8,88
Mkt. cap
1,94 mjd
Avg. vol.
2,41 m
Volume
15,00
52-wk high
USD 11,42
52-wk low
USD 4,56
EPS
-USD 2,80
Beta
1,81
Shares outstanding
217,67 m
No. of employees
3 k
Open
USD 9,26
High
USD 9,43
Low
USD 8,88
Mkt. cap
1,94 mjd
Avg. vol.
2,41 m
Volume
15,00
52-wk high
USD 11,42
52-wk low
USD 4,56
EPS
-USD 2,80
Beta
1,81
Shares outstanding
217,67 m
No. of employees
3 k
Analyst outlook
Analyst Ratings
Based on 2 analysts giving stock ratings to NEOG in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12 month forecast
Based on 2 Wall Street analysts offering 12 month price targets for NEOG in the last 3 months.
Highest
Current USD 8,93
USD 12,00 (+34,38%)
Average
USD 12,00 (+34,38%)
Lowest
USD 12,00 (+34,38%)
News stories
From sources across the web
Profile
Neogen Corporation is an international food safety company that provides test kits and relevant products to detect dangerous substances in food. The company was founded in 1982 and is based in Lansing, Michigan. The company serves a wide range of countries including Canada, United States, the United Kingdom, parts of Europe, Mexico and Brazil, India, and China, among others. The company operates a product line of over 100 drug detection test kits worldwide for the detection of about 300 abused and therapeutic drugs in animal treatment. In 2009, it became a vendor of the Chinese government and has been engaged in researching China-specific food safety and plant health issues. Wikipedia
About Neogen Corp
CEOJohn Adent
Employees2,97 k
Founded1982
Headquarters-
SectorMedical device
Websiteneogen.com
Last report
09 Apr. 2026
Fiscal period
Q3 2026
EPS / Est. (USD)
USD 0,09 / USD 0,05
+68,76%beat
Revenue / Est. (USD)
211,20 m / 204,62 m
+3,22%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mei 2025
Aug. 2025
Nov. 2025
Feb. 2026
Revenue
225,46 m
209,19 m
224,69 m
211,20 m
Cost of goods sold
137,20 m
114,22 m
118,01 m
112,20 m
Cost of revenue
137,20 m
114,22 m
118,01 m
112,20 m
Research and development expenses
6,31 m
5,12 m
4,56 m
3,80 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
106,70 m
105,94 m
107,50 m
98,50 m
Operating expense
113,01 m
111,06 m
112,06 m
102,30 m
Total operating expenses
250,21 m
225,28 m
230,07 m
214,50 m
Operating income
-24,75 m
-16,09 m
-5,38 m
-3,30 m
Other non operating income
-3,35 m
-1,10 m
-477,00 k
-3,10 m
EBT including unusual items
-631,20 m
43,81 m
-20,36 m
-20,30 m
EBT excluding unusual items
-47,94 m
-32,58 m
-20,36 m
-20,30 m
Income tax expense
-19,01 m
7,47 m
-4,44 m
-3,30 m
Effective tax rate
3,01%
17,05%
21,80%
16,26%
Other operating expenses
-
-
-
-
Net income
-612,20 m
36,34 m
-15,92 m
-17,00 m
Net profit margin
-271,53%
17,37%
-7,09%
-8,05%
Earnings per share
0,05
0,04
0,10
0,09
Interest and investment income
644,00 k
918,00 k
592,00 k
-
Interest expense
-17,13 m
-16,44 m
-14,85 m
-13,90 m
Net interest expenses
-16,48 m
-15,52 m
-14,26 m
-13,90 m
Depreciation and amortization charges
-
-
-
-
EBITDA
5,51 m
12,96 m
23,55 m
25,62 m
Gain or loss from assets sale
-124,00 k
-75,69 m
267,00 k
224,00 k
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more